Sydney Price

Payment processing company StoneCo Ltd. and its investors have received preliminary approval from a New York federal judge of their $26.8 million settlement ending claims the company misled about its role in the failure of a merchant lending program it once offered in Brazil.

Acadia Healthcare Inks Investor Settlement Days Before Trial

Acadia Healthcare Co. Inc. and plaintiffs in a securities class action accusing the company of misleading investors about the strength of its United Kingdom operations have reached a settlement in principle, avoiding a trial that was set for later this month.

Medical device company Inspire Medical Systems has been hit with a proposed investor class action alleging its shares dropped by nearly a third of their value after the public learned it concealed low demand and rollout shortcomings associated with its newest sleep apnea device.

Athena Bitcoin Inc., an operator of so-called bitcoin automated teller machines, was hit with a consumer's proposed class action in Florida federal court accusing it of charging customers excessive and undisclosed fees and operating without a proper money transmitting license.

PayPal has for a second time beat a proposed class action accusing it of illegally boosting online retail prices with restrictive merchant agreements, but the consumers have one more chance to amend.

Digital banking services company Fiserv was hit with a proposed shareholder class action on Tuesday accusing it of basing its 2025 financial guidance on misguided "assumptions," causing shares to plummet by nearly half their value last week.

An investor in Florida-based First National Bank of Pasco hit the bank with a lawsuit alleging that its inability to manage lending to cannabis industry operators has made it prone to regulatory scrutiny and financial harm, including a recent investigation by the Office of the Comptroller of the Currency.

Biopharmaceutical company BioAge Labs Inc. has, for now, escaped a suit alleging investors were hurt by plummeting share prices after the company unexpectedly halted a clinical trial for a weight loss drug, saying that the investors failed to plausibly show the company did not properly disclose risks to the trial.

Biopharmaceutical company BioAge Labs Inc. has, for now, escaped a suit alleging investors were hurt by plummeting share prices after the company unexpectedly halted a clinical trial for a weight loss drug, saying that the investors failed to plausibly show the company did not properly disclose risks to the trial.